Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 1.00 |
| ▸ | BCR | P11274 | 11/20 | 1.00 |
| ▸ | PRKCA | P17252 | 9/20 | 1.00 |
| ▸ | SRC | P12931 | 6/20 | 1.00 |
| ▸ | EGFR | P00533 | 3/20 | 1.00 |
| ▸ | PLK1 | P53350 | 1/20 | 0.71 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.67 |
| ▸ | PRKACA | P17612 | 1/20 | 0.67 |
| ▸ | PRKACG | P22612 | 1/20 | 0.67 |
| ▸ | PRKACB | P22694 | 1/20 | 0.67 |
| ▸ | CDK2 | P24941 | 5/20 | 0.64 |
| ▸ | CDK4 | P11802 | 4/20 | 0.64 |
| ▸ | GSK3B | P49841 | 2/20 | 0.64 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.60 |
| ▸ | CDK9 | P50750 | 3/20 | 0.60 |
| ▸ | CDK1 | P06493 | 2/20 | 0.60 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.60 |
| ▸ | CDK7 | P50613 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824007 | 0.91 | ABL1 (0.84) | ABL1BCRPRKCASRCEGFR | |
| SCHEMBL1144 | 0.89 | ABL1 (1.00) | ABL1BCRPRKCASRCEGFR | |
| SCHEMBL3864320 | 0.86 | ABL1 (0.76) | ABL1BCRPRKCASRCEGFR | |
| SCHEMBL4734622 | 0.86 | ABL1 (0.76) | ABL1BCRPRKCASRCEGFR | |
| SCHEMBL4733637 | 0.86 | ABL1 (0.76) | ABL1BCRPRKCASRCEGFR | |
| SCHEMBL4739200 | 0.86 | ABL1 (0.76) | ABL1BCRPRKCASRCEGFR | |
| SCHEMBL6156799 | 0.85 | ABL1 (0.73) | ABL1BCRPRKCASRCEGFR | |
| SCHEMBL2009 | 0.85 | ABL1 (0.74) | ABL1BCRPRKCASRCEGFR | |
| SCHEMBL4733339 | 0.84 | PLK1 (0.75) | ABL1BCRPRKCASRCEGFR | |
| SCHEMBL4735511 | 0.84 | PLK1 (0.75) | ABL1BCRPRKCASRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110906-A | Novel use of conjugates | 中山万汉制药有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-112079821-A | Conjugate formed by orlistat and phenylaminopyrimidine compound and preparation method and application thereof | 中山万汉制药有限公司 | 2020-12-15 | — | — | CN | claimed |
| CN-112043708-A | Anti-hepatitis B use of conjugates | 中山万汉制药有限公司 | 2020-12-08 | — | — | CN | claimed |
| EP-1721609-A2 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC Biotech AG (DE) | 2006-11-15 | — | — | EP | claimed |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2006-09-28 | — | — | US | claimed |
| EP-1395261-B1 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | GPC BIOTECH AG (DE) | 2006-06-28 | — | — | EP | claimed |
| EP-1395261-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | Axxima Pharmaceuticals Aktiengesellschaft (DE) | 2004-03-10 | — | — | EP | claimed |
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | GPC BIOTECH FORSCHUNGSGESELLSCHAFT MBH (DE) | 2003-09-18 | — | — | US | claimed |
| WO-2002093164-A2 | PYRIDYLPYRIMIDINE DERIVATIVES AS EFFECTIVE COMPOUNDS AGAINST PRION DISEASES | AXXIMA PHARMACEUTICALS AG (DE) | 2002-11-21 | — | — | WO | claimed |
| EP-0564409-B1 | Pyrimidin derivatives and process for their preparation | NOVARTIS AG (CH) | 2000-01-19 | — | — | EP | claimed |
| US-5521184-A | ANTITUMOR AGENTS; imatinib mesylate | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | claimed |
| EP-0564409-A1 | Pyrimidin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-10-06 | — | — | EP | claimed |
| JP-6087834-A | — | — | None | — | — | JP | disclosed |
| CN-112110906-A | Novel use of conjugates | 中山万汉制药有限公司 | 2020-12-22 | — | — | CN | disclosed |
| CN-112079821-A | Conjugate formed by orlistat and phenylaminopyrimidine compound and preparation method and application thereof | 中山万汉制药有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-112043708-A | Anti-hepatitis B use of conjugates | 中山万汉制药有限公司 | 2020-12-08 | — | — | CN | disclosed |
| EP-0564409-B1 | Pyrimidin derivatives and process for their preparation | NOVARTIS AG (CH) | 2000-01-19 | — | — | EP | disclosed |
| US-5521184-A | ANTITUMOR AGENTS; imatinib mesylate | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
| JP-H0687834-A | PYRIMIDINE DERIVATIVE AND ITS PREPARATION | CIBA GEIGY AG | 1994-03-29 | — | — | JP | disclosed |
| EP-0564409-A1 | Pyrimidin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176443-A1 | Pyridylpyrimidine derivatives as effective compounds against prion diseases | PRNP, PPM1D, PPM1F | ABL1 901/4885BCR 1338/4885PRKCA 138/4885 |
| US-20060217404-A1 | Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases | PRNP, PPM1D, PPM1F | ABL1 904/4885BCR 1230/4885PRKCA 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.